Publications

2022

• Aggarwal, A. et al. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature microbiology 7.
• Akbil, B. et al. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of clinical immunology 42.
• Arora, P. et al. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell reports 39.
• Arora, P. et al. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Cellular & molecular immunology 19.
• Arora, P. et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell host & microbe 30.
• Chen, H. et al. Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel. EMBO Mol Med 14.
• Demichev, V. et al. A proteomic survival predictor for COVID-19 patients in intensive care. PLOS Digit Health 1.
• Dombret, S., Skapenko, A. & Schulze-Koops, H. Reactive arthritis after SARS-CoV-2 infection. RMD open 8.
• Dulovic, A. et al. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in immunology 13.
• Ercanoglu, M. S. et al. No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. iScience 25.
• Freise, N. F. et al. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. Scientific reports 12.
• Gliga, S. et al. Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients. Clinical infectious diseases.
• Gruell, H. et al. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell host & microbe 30.
• Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature medicine 28.
• Gruell, H. et al. Antibody-mediated neutralization of SARS-CoV-2. Immunity 55.
• Habermann, E. et al. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD open 8.
• Hirsch, C. et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews 6.
• Hoffmann, M. et al. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. mBio 13.
• Kantauskaite, M. et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. American journal of transplantation 22.
• Kolb, P., Giese, S., Voll, R. E., Hengel, H. & Falcone, V. Immune complexes as culprits of immunopathology in severe COVID-19. Medical microbiology and immunology.
• Kreuzberger, N. et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database of Systematic Reviews 8.
• Li, Q. et al. Immune response in COVID-19: what is next? Cell death and differentiation 29.
• Liu, Z. et al. Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Frontiers in immunology 13.
• Malin, J. J. et al. SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood advances 6.
• Meyer-Arndt, L. et al. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. Journal of immunology 208.
• Momsen Reincke, S. et al. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science 375.
• Peter, L. et al. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular therapy. Methods & clinical development 25.
• Schultze, J. L., Büttner, M. & Becker, M. Swarm immunology: harnessing blockchain technology and artificial intelligence in human immunology. Nature reviews - Immunology 22.
• Schulz, S. R. et al. Augmented Neutralization of SARS-CoV-2 Omicron Variant by Boost Vaccination and Monoclonal Antibodies. European journal of immunology 52.
• Schwarz, T. et al. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Multiple Sclerosis Journal 28.
• Theobald, S. J. et al. Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS‐CoV‐2 mRNA vaccination. EMBO Mol Med 14.
• Tober-Lau, P. et al. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging infectious diseases 28.
• Vanshylla, K. et al. Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. The Lancet Infectious Diseases 22.
• Wang, Z. et al. Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. The Journal of experimental medicine 219.
• Weber, S. et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PloS one 17.

2021

• Arora, P. et al. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cellular & molecular immunology 18.
• Arora, P., Pöhlmann, S. & Hoffmann, M. Mutation D614G increases SARS-CoV-2 transmission. Signal transduction and targeted therapy 6.
• Arora, P. et al. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell reports 37.
• Augustin, M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet regional health. Europe 6.
• Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature medicine 27.
• Bošnjak, B. et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Frontiers in immunology 12.
• Burnett, D. L. et al. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity 54.
• Demichev, V. et al. A time-resolved proteomic and prognostic map of COVID-19. Cell Systems 12.
• Eberhardt, K. A. et al. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms 9.
• Fischer, D. S. et al. Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'. Nature communications 12.
• Gaitzsch, E. et al. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. HemaSphere 5.
• Georg, P. et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 185.
• Gieselmann, L. et al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nature protocols 16.
• Gornyk, D. et al. SARS-CoV-2-Seroprävalenz in Deutschland: Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen. Dtsch Arztebl Int 118.
• Groß, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 75.
• Halwe, S. et al. Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses 2021.
• Hempel, T. et al. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chem. Sci. 12.
• Hennig, V. et al. Increased risk of chronic fatigue and hair loss following COVID-19 in individuals with hypohidrotic ectodermal dysplasia. Orphanet journal of rare diseases 16.
• Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet Respiratory Medicine 9.
• Hoff, N.-P. et al. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction. European journal of medical research 26.
• Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell reports 36.
• Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184.
• Hoffmann, M. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell reports 35.
• Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185.
• Jones, T. C. et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 373.
• Kreuzberger, N. et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane database of systematic reviews 9.
• Kreuzberger, N. et al. Persistence of immunoglobulin G after natural infection with SARS-CoV-2. Cochrane Database of Systematic Reviews 3.
• Loyal, L. et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science 374.
• Mahoney, M. et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the National Academy of Sciences of the United States of America 118.
• Mühlemann, B. et al. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalised COVID-19 patients - results from a prospective observational study. Clinical microbiology and infection 27.
• Oestreich, M., Chen, D., Schultze, J. L., Fritz, M. & Becker, M. Privacy considerations for sharing genomics data. EXCLI journal 20.
• Peter, A. S. et al. A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. European journal of immunology 52.
• Renn, M. et al. Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. Pharmacology & Therapeutics 228.
• Ruhl, L. et al. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal transduction and targeted therapy 6.
• Schmidt, K. G. et al. SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. Frontiers in immunology 12.
• Schrezenmeier, E. et al. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in immunology 12.
• Schuh, W. et al. A surrogate cell-based SARS-CoV-2 spike blocking assay. European journal of immunology 51.
• Schulz, S. R. et al. Augmented Neutralization of SARS-CoV-2 Omicron Variant by Boost Vaccination and Monoclonal Antibodies. European journal of immunology 52.
• Schwarz, T. et al. SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. Frontiers in immunology 12.
• Schwarz, T. et al. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging infectious diseases 27.
• Theobald, S. J. et al. Long–lived macrophage reprogramming drives spike protein–mediated inflammasome activation in COVID–19. EMBO Mol Med 13.
• Thibeault, C. et al. Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection 49.
• Tober-Lau, P. et al. Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021. Emerging infectious diseases 27.
• Tober-Lau, P. et al. Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. The Lancet Respiratory Medicine 9.
• Trimpert, J. et al. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Viruses 13.
• Vanshylla, K. et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell host & microbe 29.
• Vanshylla, K. et al. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host & microbe 30.
• Vesper, N. et al. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants. Frontiers in immunology 12.
• Wagner, K. I. et al. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection. Cell reports 38.
• Warnat-Herresthal S, Schultze H, Shastry KL, et al. Swarm Learning for decentralized and confidential clinical machine learning. Nature 594.
• Wendisch, D. et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184.
• Witkowski, M. et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature 600.

2020

• Bacher, P. et al. Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity 53.

Preprints

• Ankerhold, J. et al. Enhanced FcγRIII/CD16 activation by discrete ligands as independent correlates of disease severity in COVID-19 patients (2021).
• Chen H, Maul-Pavicic A, Holzer M, et al. Immune Complex Solubility and Size Govern Fc-Gamma Receptor Responses: A Scalable Cell-Based Reporter System
• Reincke, S. M. et al. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies.
• Rodiah, I. et al. Age-specific Contribution of Contacts to Transmission of SARS-CoV-2 in Germany.